NEW YORK (GenomeWeb News) – Med BioGene today announced it has amended its commercialization agreement with Precision Therapeutics for Med Bio's LungExpress Dx test.

The Vancouver, British Columbia-based company also provided an update on its litigation against Signal Genetics and Respira Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.